secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOLIFE SOLUTIONS INC (BLFS)
CIK:        0000834365
Form:       8-K
Filed at:   2026-05-07T23:59:59+00:00
Accession:  0001628280-26-032123
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioLife Solutions Q1 revenue up 25% YoY to $27.5M; net income $1.2M
-------------------------------------------------------------------

- Total revenue $27.5M, +25% YoY from $22.1M; GAAP net income $1.2M vs $0.3M in Q1 2025.
- Non-GAAP adjusted EBITDA $6.2M (22% of revenue) vs $5.4M (24% of revenue) in Q1 2025.
- GAAP EPS $0.02; GAAP gross margin 64% (down from 67% YoY); adjusted gross margin 64% (down from 68%).
- Reiterated FY 2026 guidance: revenue $112.5-115.0M, mid-60% gross margin, full-year net income.
- Biopreservation media embedded in 17 commercial CGTs and ~250 ongoing U.S. clinical trials (70% share).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/834365/000162828026032123/0001628280-26-032123-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/834365/000162828026032123/blfs-20260507.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-032123

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer